Use of hepadnavirus core proteins as vaccine platforms

Expert Review of Vaccines

Volumn 8, Issue 11, 2009, Pages 1565-1573

  Whitacre, David C ^a,b   Lee, Byung O ^a   Milich, David R ^a  

^a Vaccine Research Institute of San Diego   (United States)

^b VLP Biotech Inc   (United States)

Author keywords

HBcAg; HBV subunit vaccine platform; Virus like particle; WHcAg

Indexed keywords

2,4 DINITROPHENOL; ACAM FLU A VACCINE; CORE PROTEIN; EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; ICC 1132; INFLUENZA VACCINE; MALARIA VACCINE; MALARIAVAX; MALARIAVAX VACCINE; MONTANIDE ISA 720; UNCLASSIFIED DRUG; VIRUS PROTEIN; VLP VACCINE;

CLINICAL TRIAL; HEPADNAVIRUS; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; INFLUENZA; MALARIA; NONHUMAN; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; REVIEW; VIRION;

CARRIER PROTEINS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIROSOME;

EID: 70449337697     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.121     Document Type: Review

References (78)

1. Peters B, Sidney J, Bourne P et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol. 3(3), e91 (2005). •• The authors describe the conception, establishment, organization and goals of the Immune Epitope Database (www.iedb.org), which contains a publicly-searchable database of known immune epitopes. The epitopes and the information about them are useful for the design of subunit vaccines.
2. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006).
3. Clarke BE, Newton SE, Carroll AR et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330(6146), 381-384 (1987). • Original description of the recombinant virus-like particle (VLP) used to display a foreign peptide epitope.
4. Howard CR. The biology of hepadnaviruses. J. Gen. Virol. 67(Pt 7), 1215-1235 (1986).
5. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64(1), 51-68 (2000).
6. Hoofnagle JH, Gerety RJ, Barker LF. Antibody to hepatitis-B-virus core in man. Lancet 2(7834), 869-873 (1973).
7. Milich DR, McLachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329(6139), 547-549 (1987). • First description of intermolecular/ intrastructural T-cell help for HBV antigens. (Pubitemid 17124776)
8. Bottcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386(6620), 88-91 (1997). (Pubitemid 27130926)
9. Conway JF, Cheng N, Zlotnick A, Wingfield PT, Stahl SJ, Steven AC. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature 386(6620), 91-94 (1997). (Pubitemid 27130927)
10. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3(6), 771-780 (1999).
11. Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 63(2), 798-808 (1989). (Pubitemid 19057248)
12. Schodel F, Moriarty AM, Peterson DL et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol. 66(1), 106-114 (1992). •• Description of how insert position within HBV core antigen (HBcAg) affects the immunogenicity of the inserted foreign epitope.
13. Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J. Virol. 64(7), 3319-3330 (1990). (Pubitemid 20219537)
14. Watts NR, Conway JF, Cheng N et al. The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO J. 21(5), 876-884 (2002). (Pubitemid 34206161)
15. Billaud JN, Peterson D, Lee BO et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25(9), 1593-1606 (2007). • Here the use of the rodent hepadnaviral core proteins is presented as a VLP vaccine carrier to avoid the limitations of the HBcAg-based platform. (Pubitemid 46108210)
16. Billaud JN, Peterson D, Schodel F et al. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J. Virol. 79(21), 13641-13655 (2005). (Pubitemid 41508176)
17. Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 20(3-4), 370-376 (2001). (Pubitemid 32973778)
18. Billaud JN, Peterson D, Barr M et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol. 79(21), 13656-13666 (2005). (Pubitemid 41508177)
19. Walker A, Skamel C, Vorreiter J, Nassal M. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. J. Biol. Chem. 283(48), 33508-33515 (2008). • By splitting the core protein into two halves, the authors show that very large inserts can be accommodated at the site of the immunodominant loop.
20. Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl Acad. Sci. USA 83(6), 1578-1582 (1986). (Pubitemid 16018607)
21. Ziermann R, Ganem D. Homologous and heterologous complementation of HBV and WHV capsid and polymerase functions in RNA encapsidation. Virology 219(2), 350-356 (1996). (Pubitemid 26189058)
22. Huang Z, Santi L, LePore K, Kilbourne J, Arntzen CJ, Mason HS. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 24(14), 2506-2513 (2006). (Pubitemid 43290380)
23. Milich DR, McLachlan A, Stahl S et al. Comparative immunogenicity of hepatitis B virus core and E antigens. J. Immunol. 141(10), 3617-3624 (1988). (Pubitemid 18275549)
24. Zheng J, Schodel F, Peterson DL. The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern. J. Biol. Chem. 267(13), 9422-9429 (1992).
25. Jegerlehner A, Tissot A, Lechner F et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20(25-26), 3104-3112 (2002). (Pubitemid 34893219)
26. Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J. Immunol. 32(11), 3305-3314 (2002). (Pubitemid 35414888)
27. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibodydependent NK cell activity. J. Immunol. 172(9), 5598-5605 (2004). (Pubitemid 38542062)
28. Fu TM, Grimm KM, Citron MP et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27(9), 1440-1447 (2009).
29. Beesley KM, Francis MJ, Clarke BE et al. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties. Biotechnology (NY) 8(7), 644-649 (1990).
30. Borisova GP, Berzins I, Pushko PM et al. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett. 259(1), 121-124 (1989). (Pubitemid 20009961)
31. Brown AL, Francis MJ, Hastings GZ et al. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine 9(8), 595-601 (1991).
32. Clarke BE, Brown AL, Grace KG et al. Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria. J. Gen. Virol. 71(Pt 5), 1109-1117 (1990).
33. Francis MJ, Hastings GZ, Brown AL et al. Immunological properties of hepatitis B core antigen fusion proteins. Proc. Natl Acad. Sci. USA 87(7), 2545-2549 (1990).
34. Moriarty A, McGee JS, Winslow B et al. Expression of HIV gag and env B-cell epitopes on the surface of HBV core particles and analysis of the immune responses generated to those epitopes. In: Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Press, NY, USA, 225 (1990).
35. Schodel F, Milich DR, Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol. 145(12), 4317-4321 (1990).
36. Stahl SJ, Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl Acad. Sci. USA 86(16), 6283-6287 (1989). (Pubitemid 19210636)
37. von Brunn A, Brand M, Reichhuber C, Morys-Wortmann C, Deinhardt F, Schodel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 11(8), 817-824 (1993). (Pubitemid 23180238)
38. Karpenko LI, Ivanisenko VA, Pika IA et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 18(4), 329-337 (2000). • This group analyzed the features of HBcAg foreign inserts that affect the ability of the chimeric particles to assemble.
39. Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA 96(5), 1915-1920 (1999).
40. Skamel C, Ploss M, Bottcher B et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J. Biol. Chem. 281(25), 17474-17481 (2006). (Pubitemid 43909555)
41. Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J. Immunol. 35(2), 655-665 (2005). (Pubitemid 40331342)
42. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 94(6), 744-748 (1981).
43. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J. Clin. Invest. 91(6), 2586-2595 (1993). (Pubitemid 23182513)
44. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13, 29-60 (1995).
45. Milich DR, McLachlan A, Moriarty A, Thornton GB. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J. Immunol. 139(4), 1223-1231 (1987). (Pubitemid 17134185)
46. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234(4782), 1398-1401 (1986). •• First description of how HBcAg could act as a T-cell-independent antigen. (Pubitemid 17210220)
47. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 262(5138), 1448-1451 (1993). (Pubitemid 24035067)
48. Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl Acad. Sci. USA 94(26), 14648-14653 (1997). (Pubitemid 28041428)
49. Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl Acad. Sci. USA 95(16), 9477-9481 (1998). (Pubitemid 28506256)
50. Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J. Immunol. 175(5), 3165-3176 (2005). (Pubitemid 41170538)
51. Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. J. Gen. Virol. 86(Pt 1), 75-84 (2005). (Pubitemid 40081152)
52. Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J. Virol. 81(5), 2535-2536 (2007). (Pubitemid 46303370)
53. Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G. Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. J. Gen. Virol. 86(Pt 2), 323-331 (2005). (Pubitemid 40227943)
54. Lee BO, Tucker A, Frelin L et al. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 182(11), 6670-6681 (2009).
55. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 28(6), 799-809 (2008).
56. Schodel F, Wirtz R, Peterson D et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180(3), 1037-1046 (1994). •• An HBcAg-based vaccine candidate is shown to elicit 100% protection against a murine malarial infection. (Pubitemid 24256616)
57. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44(2-3), 98-114 (2001). (Pubitemid 32757388)
58. Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328(6127), 257-259 (1987). (Pubitemid 17108275)
59. Zavala F, Tam JP, Hollingdale MR et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228(4706), 1436-1440 (1985). (Pubitemid 15041321)
60. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207(4426), 71-73 (1980). (Pubitemid 10142301)
61. Zavala F, Tam JP, Barr PJ et al. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med. 166(5), 1591-1596 (1987). (Pubitemid 18051448)
62. Schodel F, Peterson D, Milich DR, Charoenvit Y, Sadoff J, Wirtz R. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge. Behring Inst. Mitt. (98), 114-119 (1997).
63. Milich DR, Hughes J, Jones J, Sallberg M, Phillips TR. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine 20(5-6), 771-788 (2001). (Pubitemid 34015817)
64. Birkett A, Lyons K, Schmidt A et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. 70(12), 6860-6870 (2002). (Pubitemid 35387919)
65. Langermans JA, Schmidt A, Vervenne RA et al. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria vaccine ICC-1132 in macaques. Vaccine 23(41), 4935-4943 (2005). (Pubitemid 41242870)
66. Gregson AL, Oliveira G, Othoro C et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One 3(2), e1556 (2008). (Pubitemid 351836831)
67. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72(11), 6519-6527 (2004).
68. Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun. 73(6), 3587-3597 (2005). (Pubitemid 40745903)
69. Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23(7), 857-864 (2005).
70. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 65(10), 5491-5498 (1991).
71. Zebedee SL, Lamb RA. Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucleic Acids Res. 17(7), 2870 (1989).
72. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999). (Pubitemid 29474420)
73. De Filette M, Min Jou W, Birkett A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337(1), 149-161 (2005). (Pubitemid 40725448)
74. Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol. 49, 303-326 (2009).
75. Ionescu RM, Przysiecki CT, Liang X et al. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci. 95(1), 70-79 (2006).
76. Murata Y, Lightfoote PM, Rose RC, Walsh EE. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol. J. 6, 81 (2009).
77. Kumar S, Ochoa W, Singh P et al. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 388(1), 185-190 (2009).
78. Denis J, Acosta-Ramirez E, Zhao Y et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26(27-28), 3395-3403 (2008).